Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Elicio Therapeutics (ELTX) Operating Expenses (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Operating Expenses readings, the most recent being $9.4 million for Q4 2023.

  • On a quarterly basis, Operating Expenses rose 57.56% to $9.4 million in Q4 2023 year-over-year; TTM through Dec 2023 was $35.7 million, a 4.84% increase, with the full-year FY2025 number at $37.7 million, down 16.17% from a year prior.
  • Operating Expenses hit $9.4 million in Q4 2023 for Elicio Therapeutics, down from $10.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $20.3 million in Q1 2021 to a low of $5.8 million in Q3 2022.
  • Median Operating Expenses over the past 4 years was $11.9 million (2020), compared with a mean of $12.2 million.
  • Biggest five-year swings in Operating Expenses: crashed 66.82% in 2022 and later surged 86.67% in 2023.
  • Elicio Therapeutics' Operating Expenses stood at $14.3 million in 2020, then decreased by 20.98% to $11.3 million in 2021, then tumbled by 47.28% to $6.0 million in 2022, then soared by 57.56% to $9.4 million in 2023.
  • The last three reported values for Operating Expenses were $9.4 million (Q4 2023), $10.8 million (Q3 2023), and $7.8 million (Q2 2023) per Business Quant data.